FemTech has matured unevenly across the conditions it covers. Fertility benefits and clinics attracted the most institutional capital, with Carrot, Maven and Kindbody establishing the reference points for employer-contracted models. Cycle and pregnancy apps followed consumer health dynamics and the recent correction with them. Menopause, pelvic health and gynaecological devices sit earlier in their venture cycle. Capital that has moved in 2024 and 2025 has concentrated in operators with contracted employer or payer revenue rather than pure consumer subscription.

The investor mix has to follow the business model rather than the label. Employer benefits-led FemTech operators draw the healthcare-focused funds active in maternity and family benefits - General Catalyst Health, 7wireVentures, Define Ventures, Oxeon, F-Prime; consumer cycle and pregnancy apps draw consumer health investors; clinical menopause and pelvic health platforms draw healthcare-focused funds with women's health partners; and devices and diagnostics draw life-sciences specialists like OrbiMed and the medtech CVCs at J&J and Reckitt where the strategic fit is direct. Flow has direct relationships across this set and targets funds with recent leads in the matching condition area and business model.

Flow has experience running VC fundraising processes for FemTech companies across fertility clinics and digital fertility benefits, cycle and reproductive health apps, pregnancy and postpartum platforms, menopause and midlife care, and pelvic health and women's health devices and diagnostics. Our extensive investor network spans early-stage seed funds, growth-stage investors, and strategic and corporate VC arms.